Skip to main content

Advances in CAR-T Immunotherapy

Edited by: Profs. Marko Radic, Djordje Atanackovic and Tim Luetkens
In-house Editors: Drs. Linda Gummlich and Akila Sridhar


New Content Item

Chimeric antigen receptor (CAR) T cells therapies, as a novel modality in cancer immunotherapy, provide a quantum leap in the treatment of cancer.  In recognition of the new advances that the CAR approach represents in hematological malignancies, the Food and Drug Administration (FDA) approved two separate cell-based gene therapies, one from Novartis (Kamryah) the other from Gilead (Yescarta), for treatment of B cell leukemias.  These concrete steps that advance the CAR therapy into the clinic, providing the backdrop and motivation to assist the integration of the CAR-T immunotherapy into the standard treatment modalities of cancer.  We envision that accelerated progress with clinical trials of CAR-T cells, the proper dosing of engineered T cells along with optimized GMP-compliant production of patient-derived T lymphocytes, combination therapies using CAR-T cells and additional chemo- and immune-therapies, and increased safety considerations with diminished side-effects will remain the focus of scientific investigations.  

Acknowledging this leap in science, from the lab to the clinic, BMC Cancer and BMC Biotechnology, present the recent advances in the development, applications and safety of CAR-T immunotherapy in this collection.

  1. Treatment of cancers has largely benefited from the development of immunotherapy. In particular, Chimeric Antigen Receptor (CAR) redirected T cells have demonstrated impressive efficacy against B-cell malignan...

    Authors: Pierre Dillard, Maren Lie, Elizabeth Baken, Viola Hélène Lobert, Emmanuelle Benard, Hakan Köksal, Else Marit Inderberg and Sébastien Wälchli

    Citation: BMC Biotechnology 2020 20:30

    Content type: Methodology article

    Published on:

  2. Glioblastoma multiform (GBM), a malignant brain tumour, has a very often poor prognosis. The therapeutic approach is represented by surgery followed by radiotherapy and chemotherapy. Hypoxia is a factor that c...

    Authors: Vincenzo Gangemi, Chiara Mignogna, Giusy Guzzi, Angelo Lavano, Salvatore Bongarzone, Giuseppe Lucio Cascini and Umberto Sabatini

    Citation: BMC Cancer 2019 19:1197

    Content type: Case report

    Published on:

  3. Simultaneous advances in gene editing, T cell engineering and biotechnology currently provide an opportunity for rapid progress in medicine. The approval of chimeric antigen receptor (CAR) T cell therapies by ...

    Authors: Noah H. Richardson, Jordan B. Luttrell, Jonathan S. Bryant, Damian Chamberlain, Saleem Khawaja, Indira Neeli and Marko Radic

    Citation: BMC Biotechnology 2019 19:84

    Content type: Review

    Published on:

  4. Glioma is a common malignant tumours in the central nervous system (CNS), that exhibits high morbidity, a low cure rate, and a high recurrence rate. Currently, immune cells are increasingly known to play roles...

    Authors: Qiu-Yue Zhong, Er-Xi Fan, Guang-Yong Feng, Qi-Ying Chen, Xiao-Xia Gou, Guo-Jun Yue and Gui-hai Zhang

    Citation: BMC Cancer 2019 19:1116

    Content type: Database

    Published on:

  5. Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to...

    Authors: Lena Andersch, Josefine Radke, Anika Klaus, Silke Schwiebert, Annika Winkler, Elisa Schumann, Laura Grunewald, Felix Zirngibl, Carina Flemmig, Michael C. Jensen, Claudia Rossig, Antonia Joussen, Anton Henssen, Angelika Eggert, Johannes H. Schulte and Annette Künkele

    Citation: BMC Cancer 2019 19:895

    Content type: Research article

    Published on:

  6. Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity. Chimeric antigen receptor (CAR)...

    Authors: Alexandre Juillerat, Diane Tkach, Brian W. Busser, Sonal Temburni, Julien Valton, Aymeric Duclert, Laurent Poirot, Stéphane Depil and Philippe Duchateau

    Citation: BMC Biotechnology 2019 19:44

    Content type: Research article

    Published on:

  7. Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by long-term human T-cell leukemia virus type I (HTLV-1) infection. Survivin-responsive, conditionally replicating adenoviruses reg...

    Authors: Shinsuke Suzuki, Hiroki Kofune, Kimiharu Uozumi, Makoto Yoshimitsu, Naomichi Arima, Kenji Ishitsuka, Shin-ichi Ueno and Ken-ichiro Kosai

    Citation: BMC Cancer 2019 19:516

    Content type: Research article

    Published on:

  8. Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis. We ...

    Authors: Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama and Yoshitaka Okamoto

    Citation: BMC Cancer 2018 18:1254

    Content type: Research article

    Published on:

  9. Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantat...

    Authors: Shupeng Wen, Zhiyun Niu, Lina Xing, Ying Wang, Hang Li, Na Kuang, Jianmin Luo, Xuejun Zhang and Fuxu Wang

    Citation: BMC Cancer 2018 18:1143

    Content type: Case report

    Published on:

  10. Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies.

    Authors: Hui Zhou, Yuling Luo, Sha Zhu, Xi Wang, Yunuo Zhao, Xuejin Ou, Tao Zhang and Xuelei Ma

    Citation: BMC Cancer 2018 18:929

    Content type: Research article

    Published on:

  11. Effective gene-delivery systems for primary human T cell engineering are useful tools for both basic research and clinical immunotherapy applications. Pseudovirus-based systems and electro-transfection are the...

    Authors: Zhang Zhang, Shunfang Qiu, Xiaopeng Zhang and Wei Chen

    Citation: BMC Biotechnology 2018 18:4

    Content type: Methodology article

    Published on:

  12. Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused substantial tumor regression in several clinical trials. However,...

    Authors: Dennis C. Harrer, Bianca Simon, Shin-ichiro Fujii, Kanako Shimizu, Ugur Uslu, Gerold Schuler, Kerstin F. Gerer, Stefanie Hoyer, Jan Dörrie and Niels Schaft

    Citation: BMC Cancer 2017 17:551

    Content type: Research article

    Published on:

  13. The T-cell receptor (TCR), located on the surface of T cells, is responsible for the recognition of the antigen-major histocompatibility complex, leading to the initiation of an inflammatory response. Analysin...

    Authors: Elisa Rosati, C Marie Dowds, Evaggelia Liaskou, Eva Kristine Klemsdal Henriksen, Tom H Karlsen and Andre Franke

    Citation: BMC Biotechnology 2017 17:61

    Content type: Methodology article

    Published on:

  14. Adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has successfully been used to treat both chronic and acute lymphocytic leukemia as well as other hematological cancers...

    Authors: Victoria Hillerdal, Mohanraj Ramachandran, Justyna Leja and Magnus Essand

    Citation: BMC Cancer 2014 14:30

    Content type: Research article

    Published on: